ORLANDO, Fla., Jan. 31, 2005 (PRIMEZONE) -- Stanislaw R. Burzynski, M.D., Ph.D., founder and CEO of the Burzynski Clinic and President of the Burzynski Research Institute, Inc. (OTCBB:BZYR) in Houston, was a featured speaker at Neuro-Oncology 2005, the Cleveland Clinic's Annual Brain Tumor Symposium. Dr. Burzynski spoke about his pioneering research in targeted genetic cancer treatment and the development of Antineoplastons, which he and his research team discovered in the 1970s. Since that time, researchers at the Burzynski Clinic have developed these naturally occurring anti-tumor agents synthetically -- to the point that it is now possible to manufacture them commercially.
Dr. Burzynski's presentation concentrated on mechanisms of anti-tumor activity of synthetic antineoplastons, as well as statistical results of on-going clinical trials in brain stem glioma and glioblastoma multiforme. His conclusions, based on Phase II clinical trials of antineoplastons, indicated good tolerance, significant response rates and long-term survival in patients with difficult to treat primary brain tumors.
Following the presentation, Dr. Burzynski left for Paris, where he will address the 16th International Congress on Anti-Cancer Treatment (ICACT) -- February 1-4, 2005. His presentation, entitled "Targeted Therapy with Antineoplastons A10 and AS2-1 (ANP) of High Grade, Recurrent and Progressive Brain Stem Glioma (HBSG)," will support the hypothesis that antineoplastons will provide longer survival and a greater number of objective responses in HBSG patients than those receiving standard therapy, as reported by current clinical literature.
Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. BRI cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to BRI's ability to obtain regulatory approval for Antineoplastons A10 and AS2-1. BRI does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein.
The Burzynski Research Institute logo can be found at: http://www.primezone.com/newsroom/prs/?pkgid=1291